Our Current Clinical Trials

We pride ourselves on clinical advancement.

Numerous clinical research studies are conducted on an ongoing basis at Florida Medical Clinic. Studies are conducted monthly and the study length varies according to the test criteria. New and exceptional medications waiting for FDA approval are tested in similar laboratories across the United States. Nationwide patient results are monitored and evaluated by the FDA in an effort to constantly improve medical treatments.

Your physician can advise you as to your eligibility for clinical research clinic participation. Medical care, medications, and possible compensation are available to qualified patients who volunteer for the trial.

To find out what trials are currently looking for volunteers, contact your physician or look online at CenterWatch (Clinical Trials Listing Service)

Cardiology

Study Title: The IMPACT of Biotronik Home Monitoring Guided Anticoagulation on Stroke risk in Patients with Implaced ICD and CRT-D Devices

Description: The IMPACT Study will investigate the clinical benefit of the combined use of Biotronik Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and physician-directed anticoagulation in patients with implaced dual-chamber defibrillators or cardiac resynchronization therapy devices.

Eligibility: 18 Years and Older Males & Females

Gastroenterology

Study Title: Double-blind, Dose-response, Randomised, Placebo-controlled, Parallel Group, Muli-center Phase III Clinical Study on the Efficacy & Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

Description: The purpose of this study is to determine which dose of mesalazine granules compared to placebo is more effective in the prevention of recurrence of disease.

Eligibility: 30 to 80 years old Male & Females Diagnosis of Left-Sided uncomplicated diverticular disease confirmed by computed tomography (CT).

Study Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter study to assess the Efficacy and Safety of Budesonide Foram Versus Placebo in subjects with Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis.

Description: This study is to assess the efficacy & safety of budesonide foam in subjects with active mild to moderate proctitis or proctosigmoiditis.

Eligibility: 18 to 75 Years old. Male or Female. Diagnosis of Active, Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis.

Hematology

Study Title: Iron Deficiency Anemia - Intravenous Ferumoxytol

Description: A Phase III, Randomized, Double-Blind, Placebo Controlled Trial of Intravenous Ferumoxytol for the Treatment of Iron Deficiency Anemia.

Eligibility: Male or Female 18 Years and Older Iron Deficiency Anemia

Study Title: Randomized Evaluation of Efficacy & Safety of Ferric Carboxymaltose in Patients with Iron Deficiency Anemia and Impaired Renal Function

Description: The primary objective of this study is to examine the efficacy & safety (cardiovascular) of an investigational intravenous (IV) iron, Ferric Carboxymaltose (FCM), compared to IV Iron Sucrose (Venofer) in sujects who have Iron Deficiency Anemia (IDA) and impaired renal function.

Eligibility: 18 years and older Male or Female

Oncology

Study Title: Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Extrogen Receptor Positive Locally Advanced or Metastatic Breast CA who are Refractory to Letrozole or Anastrozole

Description: There are no treatments specifically approved after recurrence or progression on a NSAI. In light of the need for new treatment options for postmenopausal women after failure of prior NSAI therapy, the purpose of this Phase III study is to compare efficacy and safety of a treatment with exemestane+everolimus to exemestane+placebo in postmenopausal women with extrogen receptor positive locally advanced or metastatic breast cancer refractory to NSAI.

Eligibility: 18 Years and Older. Postmenopausal Females Diagnosis of Metastatic or locally advanced breast cancer not amendable to curative treatment by surgery or radiotherapy.

Study Title: A Randomized Double-blind, Placebo-Controlled trial of Neratinib (HKI-272) after Trastuzumab in women with Early-Stage HER-2/Neu Overexpresed/Amplified Breast Cancer.

Description: The purpose of this study is to investigate whether Neratinib can reduce the risk of perviously diagnosed HER-2 positive breast cancer from returning after treatment with Trastuzumab (Herceptin).

Eligibility: 18 Years and Older Females with Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease

Study Title: A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib + Paclitaxel (Taxol) versus Trastuzumab (Herceptin) + Paclitaxel (Taxol) as first-line treatment for ErbB-2 Positive locally recurrent or Metastatic Breast Cancer.

Description: This study is investigating the effects of an experimental drug (Neratinib) in combination with Paclitaxel (Taxol) versus Trastuzumab (Herceptin) in combination with Paclitaxel for the treatment of women who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer. The study will compare the effectiveness of each regimen in shrinking tumors and extending the lives of women with erbB-2 (HER2) positive breast cancer. The study will also compare the safety of the two regimens and as well as the quality of life of subjects recieivng either regimen.

Eligibility: 18 Years and Older Females with Advanced Breast Cancer

Rheumatology

Study Title: A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs.

Description: The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib disodium (FosD) compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding.

Eligibility: 18 years and older. Male or Female Rheumatoid Arthritis

Study Title: A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with Inadequate Response to a TNF-alpha antagonist.

Description: The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib disodium (FosD) compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate and have had an inadequate response to a single THF-alpha antagonist.

Eligibility: 18 years and older. Male or Female Rheumatoid Arthritis

  • Follow Us.